RightFit
RecruitingNot applicable

A Low-Carb Approach to Treat Type 2 Diabetes in Pediatric Patients

Carb Control: Low-Carbohydrate Dietary Intervention for Pediatric Patients With Type 2 Diabetes

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
12 Years to 18 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares a low-carb diet with a standard-carb diet in teens with type 2 diabetes. It will test the diets' effects over 24 weeks.

The purpose of this project is to test the effect of a low carb diet compared to standard carb diet among adolescents with T2D over a 24-week period.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Age 12–18.
  • Diagnosed with diabetes more than 3 months ago.
  • HbA1c between 6.5% and 8.5%. This test shows average blood sugar over the past few months.
  • Body mass index (BMI) above the 85th percentile, meaning higher than 85 out of 100 peers.
  • Negative tests for pancreatic autoantibodies, which can attack cells in the pancreas.
  • On a steady dose of diabetes drugs for 3 months: GLP-1 drugs, metformin, or SGLT-2 inhibitors.

Who can't join

  • Currently using insulin.
  • Kidney problems, shown by a creatinine blood test above 1 mg/dL.
  • Liver problems, shown by both AST and ALT liver blood tests above 100 IU/ml.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Age 12-18 * Diabetes diagnosis \>3 months to ensure stable baseline glycemic control * HbA1C between 6.5- 8.5% * BMI \>85th percentile * Negative pancreatic autoantibodies * Stable dose of anti-diabetic drugs GLP-1, metformin, SGLT-2 inhibitors, for 3 months Exclusion Criteria: * Current insulin treatment * Renal impairment measured as creatinine \> 1 mg/dL * Hepatic dysfunction measured as AST and ALT \>100 IU/ml

Study sites (1)

AL